Synta announces treatment of first patients in ALK+ lung cancer trials
06:21 EDT 3 Aug 2012 | Pharmaceutical Business Review
Synta Pharmaceuticals said first patients have been treated in two trials that are evaluating efficacy of the company's lead drug candidate, ganetespib, in patients with non-small cell lung cancer (NSCLC) whose tumors show rearrangement of the anapla..
Original Article: Synta announces treatment of first patients in ALK+ lung cancer trials
More From BioPortfolio on "Synta announces treatment of first patients in ALK+ lung cancer trials"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
